Market quotations for Astria Therapeutics Inc. reflect its standing as a clinical-stage biopharmaceutical company focused on developing therapies for immunological and allergic diseases. Recent equity tracking data records the stock trading at approximately $12.58 per share. The company's market valuation is driven primarily by investor expectations surrounding its clinical pipeline advancements, research updates, cash runway disclosures, and broader sentiment shifts across the specialized healthcare and biotechnology investment sectors.